Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.
about
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentSystems biology approaches for advancing the discovery of effective drug combinationsPrediction of Genetic Interactions Using Machine Learning and Network PropertiesCombinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers.Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanismsSynergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways.Not Just a Sum? Identifying Different Types of Interplay between Constituents in Combined InterventionsSynthetic lethality: emerging targets and opportunities in melanoma.Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders.The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agentCombinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.Assessing the potential of pharmaceuticals and their transformation products to cause mutagenic effects: Implications for gene expression profiling.The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status.Microenvironmental agonists generate phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
P2860
Q27313653-DA973A77-9BFB-46F2-9273-CE0C36BB96F8Q27702922-7D8949FD-CBC0-4D7A-BE1C-DB38200CA8E1Q28084302-2A946FE0-B3E8-4126-99F7-0E5A3DD960D2Q30277902-0231964F-ABA7-4A9A-B0FB-EEF68F870230Q30371561-1C787BCD-C0C2-49B1-8541-D8EC1771CA80Q30412090-2E4C9EA9-E057-4A78-9FDA-7D87AAF34FF5Q30418057-75A1942C-D65E-403F-85F5-3950DCC09748Q30458494-F469B8C6-E431-42D6-A245-E00A0F45C3EBQ30650188-717AEA3E-0E58-4C71-B1DC-07B79EF8174FQ33578398-145263D4-FF4A-4C65-95CC-0B9609057149Q34608239-AA876336-5111-40D0-9503-E1C334B9B656Q35597799-73F6D139-955D-4C65-A9F7-532A06771587Q36483712-F61169E9-3AE8-42A9-8989-02431972C04CQ38712272-3F93A5E9-7221-401C-8B49-575207127F89Q38737969-F6D35F74-5421-4CCD-ABC4-66BD889F6AD1Q47385759-D322198A-7A77-4CB9-A9F3-DDBD3412F8D9Q47624912-9A6261EF-D379-4ABE-BDB1-F03700A2EA27Q56514276-2A12D3D9-30DA-48FC-A0D2-0A22614D90C1
P2860
Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Synthetic lethal screening wit ...... nation therapies for melanoma.
@ast
Synthetic lethal screening wit ...... nation therapies for melanoma.
@en
type
label
Synthetic lethal screening wit ...... nation therapies for melanoma.
@ast
Synthetic lethal screening wit ...... nation therapies for melanoma.
@en
prefLabel
Synthetic lethal screening wit ...... nation therapies for melanoma.
@ast
Synthetic lethal screening wit ...... nation therapies for melanoma.
@en
P2093
P2860
P1476
Synthetic lethal screening wit ...... ination therapies for melanoma
@en
P2093
Aaron Mackey
Daniel Gioeli
Devin G Roller
Karin Jensen
Mark Axelrod
Michael J Weber
P2860
P304
P356
10.1158/1535-7163.MCT-12-0461
P577
2012-09-07T00:00:00Z